U
CYTK icon

UBS’s Cytokinetics CYTK Stock Holding History

UBS’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Hold
400
– – ﹤0.01% 10142
2014
Q2 		$2K Buy
400
+300
+300% +$1.83K ﹤0.01% 10010
2014
Q1 		$1K Buy
+100
New +$904 ﹤0.01% 10191

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's CYTK Position: Q3 2014 in Review

UBS increased its Cytokinetics (CYTK) stake by 186% in Q3 2014, buying an estimated $23.4K and bringing the position to 8,556 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #7464.

UBS first reported a position in CYTK in Q3 2013 and has held it in 5 quarters since. The position peaked at $64K in Q1 2014. 85 funds tracked by Wall St. Rank hold CYTK as of Q3 2014.

  • UBS held 8,556 shares of Cytokinetics worth $30K as of Q3 2014.
  • UBS bought 5,562 Cytokinetics shares in Q3 2014, an estimated $23.4K.
  • Cytokinetics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7464 holding.
  • UBS first reported a position in Cytokinetics in Q3 2013 and has held it in 5 quarters since.
  • UBS's Cytokinetics position peaked at $64K in Q1 2014.
  • 85 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.